Download or read book Spotlight inOncology com Issue 3 written by Boehringer Ingelheim International GmbH and published by Boehringer Ingelheim International GmbH. This book was released on with total page 75 pages. Available in PDF, EPUB and Kindle. Book excerpt: Feature article: Zurich Lung Cancer Preceptorship

Download or read book Clinical Trials in Oncology Third Edition written by Stephanie Green and published by CRC Press. This book was released on 2012-05-09 with total page 266 pages. Available in PDF, EPUB and Kindle. Book excerpt: The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background. Armed with Clinical Trials in Oncology, Third Edition, clinicians and statisticians can avoid the many hazards that can jeopardize the success of a trial.

Download or read book Index Medicus written by and published by . This book was released on 2004 with total page 2036 pages. Available in PDF, EPUB and Kindle. Book excerpt: Vols. for 1963- include as pt. 2 of the Jan. issue: Medical subject headings.

Download or read book Molecular Targets and Cancer Therapeutics Part 1 written by Faris Q.B. Alenzi and published by Bentham Science Publishers. This book was released on 2023-04-20 with total page 390 pages. Available in PDF, EPUB and Kindle. Book excerpt: Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early-stage diagnosis. Molecular Targets and Cancer presents information about cancer diagnosis and therapy in a simple way. It covers several aspects of the topic with updated information on par with medical board levels. The book features contributions from experts and includes an overview of cancer from basic biology and pathology, classifications, surveillance, prevention, diagnosis, types of cancer, treatment and prognosis. The first part of this book introduces the reader to cancer epidemiology, genetic alterations in cancer, exogenous and endogenous factors in carcinogenesis, roles for growth factors in cancer progression, cell signaling in cancer, transcription factors in cancer, and cancer genetics and epigenetics. This comprehensive guide is a valuable resource for oncologists, researchers, and all medical professionals who work in cancer care and research.

Download or read book Proteasome Inhibitors in Cancer Therapy written by Julian Adams and published by Springer Science & Business Media. This book was released on 2004-05-25 with total page 319 pages. Available in PDF, EPUB and Kindle. Book excerpt: A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (VelcadeTM) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.

Download or read book Nutraceuticals and Cancer written by Fazlul H. Sarkar and published by Springer Science & Business Media. This book was released on 2011-11-22 with total page 383 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is about Nutraceuticals in cancer therapy, specifically targeted and Adjuvant therapy. It shows several approaches for possibly reducing systemic toxicity. This book illustrates the role of several dietary agents, collectively called nutraceuticals or natural agents in the prevention and/or treatment of human malignancies known to be mediated through alterations in multiple molecular targets. This book contains sixteen chapters which begin with historical perspective on the value of natural agents in the prevention of human malignancies followed by a series of current topics on multiple nutraceuticals targeting multiple cancers. This collection would likely be useful for bringing newer generations with broader perspectives in launching cutting-edge innovative molecular research, which would certainly help in designing targeted clinical trials in order to realize the dream of customize strategies for the prevention and/or treatment of human malignancies without causing any systemic toxicity. Moreover, the knowledge gained would allow novel utilization of nutraceuticals as adjunct to both conventional chemotherapy and radiation therapy in order to improve the overall quality of life and survival of patients diagnosed with cancers.

Download or read book Highlights of Progress in Research on Cancer written by and published by . This book was released on 1957 with total page 60 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Molecular Oncology written by Edward P. Gelmann and published by Cambridge University Press. This book was released on 2013-12-19 with total page 985 pages. Available in PDF, EPUB and Kindle. Book excerpt: The genomic era has allowed enormous strides in our understanding of the molecular changes that underlie malignant transformation. Mutations have been discovered that are critical drivers of large cross-sections of human cancers. These discoveries have allowed us to find drugs that target these drivers and make important strides in treatment. Genomics and high-throughput technologies have illuminated the complexity of cancer and the facility with which cancers adapt during their natural history. The field is evolving rapidly with new discoveries and new drugs reported monthly. This book is a timely foundation for understanding in context the origins of molecular oncology and its future directions. The content reviews available technologies for the analysis of cancer tissues and genes; summaries of key oncogenic pathways from a molecular perspective; the technologies, pathways and targeted therapies of a wide range of human malignancies; and new pharmacologic therapies that have a common mechanistic target.

Download or read book Kinase Inhibitor Drugs written by Rongshi Li and published by John Wiley & Sons. This book was released on 2011-09-20 with total page 463 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive resource on case studies of marketed kinase drugs and promising drug trials Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development. In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. Kinase Inhibitor Drugs includes: Case studies from leading investigators and experts in the field that provide firsthand accounts of kinase inhibitor discovery Current thinking on kinase structure, biochemistry, and signal transduction pathways Information on state-of-the-art technologies and tools such as structure-based and fragment-based drug discovery A lineup of clinical-phase growth factor receptor inhibitors Inhibitors of cell cycle kinases The discovery of allosteric inhibitors of MEK kinase Information on pharmacogenomics and its application to kinase inhibitor clinical development

Download or read book Inhibitors of Molecular Chaperones as Therapeutic Agents written by Timothy D. Machajewski and published by Royal Society of Chemistry. This book was released on 2014 with total page 443 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to provide a comprehensive examination of the field of molecular chaperone inhibition and its application to pharmaceutical research. With several small molecule inhibitors in oncology clinical development, there is clearly intense interest in the chaperones as a molecular target. Filling a significant gap in the market by providing a detailed comparison of discovery programs across the industry, this text will find broad interest among researchers in the field of molecular chaperone pharmaceutical research, oncology research, and medicinal chemistry. Arranged into three main sections the book covers structure and function, small molecule inhibitors and concludes with a section discussing clinical perspectives. With specific chapters covering the discovery of key molecules such as, BIIB028, STA-9090, Serenex Hsp90 inhibitor, NVP-AUY922 and NVP-HSP990, this comprehensive text will be an essential treatise for researchers working in academia and industry.

Download or read book From Molecular to Modular Tumor Therapy written by Albrecht Reichle and published by Springer Science & Business Media. This book was released on 2010-09-09 with total page 552 pages. Available in PDF, EPUB and Kindle. Book excerpt: Presenting a holistic and abstract perspective of tumors, this volume aims to provide personalized diagnostic and therapeutic strategies for the control of metastatic tumor disease. Readers will find ways to record tumor biology that are based on different sciences, in addition to other strategies.

Download or read book Oncogenomics written by Franco Dammacco and published by Academic Press. This book was released on 2018-10-30 with total page 722 pages. Available in PDF, EPUB and Kindle. Book excerpt: Oncogenomics: From Basic Research to Precision Medicine offers a thorough survey of precision medicine and its diagnostic and therapeutic applications in oncology. Gathering contributions from leading international researchers in the field, chapters examine recent translational advances in oncogenomic methods and technologies, detailing novel molecular classifications of tumors as well as diagnostic and prognostic biomarkers for various types of cancers including pancreatic, gastrointestinal, breast, hematological, lung, osteotropic, genitourinary, and skin cancers. This book provides a foundation for clinical oncologists, human geneticists, and physicians to develop new targeted cancer treatments and incorporate genomic medicine into clinical practice, with particular attention paid to noninvasive diagnostic techniques such as the liquid biopsy and molecular characterization of solid malignancies. - Provides clinical oncologists, human geneticists, physicians, and students with a thorough understanding of current diagnostic and prognostic applications of genomic methods and technologies to a variety of solid malignancies - Employs current knowledge in oncogenomics towards developing therapeutic interventions for various cancer types - Features a team of internationally recognized researchers and physicians in clinical oncology, oncogenomics and precision medicine

Download or read book Nucleic Acid Drugs written by Akira Murakami and published by Springer. This book was released on 2012-07-04 with total page 189 pages. Available in PDF, EPUB and Kindle. Book excerpt: New Antisense Strategies: Chemical Synthesis of RNA Oligomers, by Junichi Yano und Gerald E. Smyth Development and Modification of Decoy Oligodeoxynucleotides for Clinical Application, by Mariana Kiomy Osako, Hironori Nakagami und Ryuichi Morishita Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides, by Ekambar R. Kandimalla und Sudhir Agrawal Delivery of Nucleic Acid Drugs, by Yan Lee und Kazunori Kataoka Aptamer: Biology to Applications, by Yoshikazu Nakamura Development and Clinical Applications of Nucleic Acid Therapeutics, by Veenu Aishwarya, Anna Kalota und Alan M. Gewirtz

Download or read book A National Cancer Clinical Trials System for the 21st Century written by Institute of Medicine and published by National Academies Press. This book was released on 2010-07-08 with total page 317 pages. Available in PDF, EPUB and Kindle. Book excerpt: The National Cancer Institute's (NCI) Clinical Trials Cooperative Group Program has played a key role in developing new and improved cancer therapies. However, the program is falling short of its potential, and the IOM recommends changes that aim to transform the Cooperative Group Program into a dynamic system that efficiently responds to emerging scientific knowledge; involves broad cooperation of stakeholders; and leverages evolving technologies to provide high-quality, practice-changing research.

Download or read book Textbook of Bladder Cancer written by Seth P. Lerner and published by CRC Press. This book was released on 2006-01-17 with total page 814 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive reference, drawing on the expertise of international leaders in the field, this text covers everything from epidemiology, pathology, and diagnosis to the treatment of both superficial and invasive bladder cancers . The book contains over 300 to quality illustrations.

Download or read book Environmental Health Perspectives written by and published by . This book was released on 2004 with total page 524 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Kinesins and Cancer written by Frank Kozielski, FSB and published by Springer. This book was released on 2015-03-02 with total page 276 pages. Available in PDF, EPUB and Kindle. Book excerpt: This interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development. Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future. The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.